Skip to main content
    U

    United Therapeutics Corporation (UTHR)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $587.88
    -3.29 (-0.56%)

    Market Cap: $25.18B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    United Therapeutics Corporation (UTHR) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    United Therapeutics reported revenue of $3.18B for the fiscal year ended Dec 31, 2025, up 10.6% from the year before. That year, net income was $1.33B with a net margin of 41.9%, operating cash flow was $1.56B and free cash flow was $1.04B. The quarter ended Sep 30, 2026 had revenue of $832.50M and net income of $258.60M.

    Revenue and Margins

    The operating margin was 46.9% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.60B, a compound annual rate of 7.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$3.18B+10.6%87.9%46.9%41.9%
    Dec 2024$2.88B+23.6%89.2%47.9%41.5%
    Dec 2023$2.33B+20.2%88.9%50.9%42.3%
    Dec 2022$1.94B+14.9%92.2%50.6%37.6%
    Dec 2021$1.69B+13.6%92.7%33.0%28.2%
    Dec 2020$1.48B+2.4%92.7%40.0%34.7%
    Dec 2019$1.45B-11.0%91.9%-12.9%-7.2%
    Dec 2018$1.63B-5.7%87.8%49.5%36.2%
    Dec 2017$1.73B+7.9%93.9%47.2%24.2%
    Dec 2016$1.60BN/A95.5%66.4%44.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 10.8% from the year before. In the quarter ended Sep 2026, net income fell 23.6% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$3.18B$2.88B$2.33B$1.94B$1.69B$1.48B$1.45B$1.63B$1.73B$1.60B
    Cost of revenue$384.40M$309.70M$257.50M$151.60M$122.50M$108.10M$117.60M$198.70M$105.70M$72.70M
    Gross profit$2.80B$2.57B$2.07B$1.78B$1.56B$1.38B$1.33B$1.43B$1.62B$1.53B
    Research and development$550.00M$481.00M$408.00M$322.90M$540.10M$357.70M$1.18B$357.90M$264.60M$147.60M
    Operating income$1.49B$1.38B$1.18B$979.70M$555.90M$593.60M-$187.60M$805.40M$814.90M$1.06B
    Net income$1.33B$1.20B$984.80M$727.30M$475.80M$514.80M-$104.50M$589.20M$417.90M$713.70M
    EBITDA$1.63B$1.46B$1.22B$989.10M$648.00M$692.80M-$119.10MN/AN/A$1.09B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$832.50M$783.30M$781.50M$790.20M$799.50M$798.60M$794.40M$735.90M$748.90M$714.90M$677.70M$614.70M
    Gross profit$733.40M$683.80M$648.10M$686.80M$698.60M$711.00M$701.90M$660.00M$665.80M$637.10M$604.80M$543.70M
    Operating income$307.80M$330.80M$325.80M$356.70M$388.50M$364.50M$382.80M$357.70M$343.10M$319.90M$356.30M$260.10M
    Net income$258.60M$333.00M$274.90M$364.30M$338.70M$309.50M$322.20M$301.30M$309.10M$278.10M$306.60M$217.10M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $1.56B were 19.8% of total assets of $7.88B, against total liabilities of $783.80M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$7.88B$7.36B$7.17B$6.04B$5.17B$4.62B$3.91B$3.40B$2.88B$2.33B
    Current assets$3.70B$3.87B$3.55B$3.38B$2.32B$2.17B$1.86B$1.77B$1.45B$1.42B
    Cash and equivalents$1.56B$1.70B$1.21B$961.20M$894.80M$738.70M$738.40M$669.20M$705.10M$1.02B
    Total liabilities$783.80M$920.00M$1.18B$1.25B$1.21B$1.22B$1.13B$593.20M$758.40M$463.40M
    Short-term debtN/A$300.00M$400.00M$0N/AN/A$250.00MN/A$250.00MN/A
    Long-term debtN/AN/A$300.00M$800.00M$800.00M$800.00M$600.00M$250.00M$250.00M$0
    Shareholder equity$7.10B$6.44B$5.98B$4.80B$3.96B$3.40B$2.78B$2.79B$2.10B$1.85B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$7.03B$7.22B$6.71B$7.88B$7.35B$7.91B$7.74B$7.36B$7.12B$6.72B$6.50B$7.17B
    Total liabilities$758.10M$819.80M$813.10M$783.80M$760.90M$734.40M$936.70M$920.00M$1.02B$1.03B$1.16B$1.18B
    Cash and equivalents$1.19B$1.80B$1.28B$1.56B$1.34B$1.59B$1.90B$1.70B$1.55B$1.36B$1.25B$1.21B
    Shareholder equity$6.28B$6.40B$5.90B$7.10B$6.59B$7.17B$6.81B$6.44B$6.10B$5.70B$5.34B$5.98B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 66.7% of operating cash flow. Share repurchases came to 96.2% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$1.56B$1.33B$978.00M$802.50M$598.20M$755.70M-$206.60M$778.40M$474.20M$643.60M
    Capital expenditures$520.50M$246.50M$230.40M$138.80M$120.80M$59.30M$83.70M$184.40M$86.30M$38.00M
    Free cash flow$1.04B$1.08B$747.60M$663.70M$477.40M$696.40M-$290.30M$594.00M$387.90M$605.60M
    Dividends paidN/AN/A$98.00M$94.30MN/A$38.50M$14.00MN/A$0$7.70M
    Share repurchases$1.00B$1.00B$0$0N/AN/AN/AN/A$250.00M$500.00M
    Investing cash flow-$551.30M$417.20M-$719.60M-$811.50M-$486.90M-$738.50M-$335.40M-$820.60M-$835.60M$48.30M
    Financing cash flow-$1.15B-$1.25B-$11.90M$75.40M$44.80M-$16.90M$611.20M$6.30M$43.30M-$497.70M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$306.50M$313.60M$463.30M$346.20M$562.10M$191.70M$461.20M$341.20M$377.20M$232.20M$376.50M$150.70M
    Capital expenditures$180.70M$108.00M$100.80M$172.90M$210.50M$62.20M$74.90M$86.70M$76.50M$45.10M$38.20M$78.70M
    Free cash flow$125.80M$205.60M$362.50M$173.30M$351.60M$129.50M$386.30M$254.50M$300.70M$187.10M$338.30M$72.00M
    Last 12 quarters

    Frequently Asked Questions About UTHR

    What is United Therapeutics' annual revenue?

    United Therapeutics reported revenue of $3.18B for the fiscal year ended Dec 31, 2025.

    How fast is United Therapeutics' revenue growing?

    Revenue was up 10.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 18.0%.

    Is United Therapeutics profitable?

    Yes. United Therapeutics reported net income of $1.33B for the fiscal year ended Dec 31, 2025, with a net margin of 41.9%.

    How much free cash flow does UTHR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $1.56B minus capital expenditures of $520.50M produced free cash flow of $1.04B.

    How much debt does United Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $1.56B.